Our Leadership: Imagination Over Iteration

Jeff Hawkins

President and Chief Executive Officer

Mr. Hawkins brings over 20 years of experience at the world’s leading life science and diagnostics companies as an accomplished business leader and inventor. Prior to Quantum-Si, he was President and Chief Executive Officer of Truvian Sciences, Inc. where he led the evolution of the company’s benchtop blood testing system from a product concept through technology feasibility and into late-stage development. Prior to Truvian, Mr. Hawkins led the Reproductive and Genetic Health Business Unit at Illumina, Inc., where he oversaw the rapid global growth of next-generation sequencing into new and emerging markets.

During his Illumina tenure, the business unit more than doubled in revenue and established clear market leadership across every major product line and geographic region. Before Illumina, Mr. Hawkins held roles of increasing responsibility across multiple functional areas for GenMark, Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an MBA from Keller Graduate School of Management. He is co-inventor on 10 issued or pending patents spanning consumables, instrumentation, optics, manufacturing methods and designs.

Jeff Keyes

Chief Financial Officer

Mr. Keyes brings over 25 years of experience in senior financial positions providing financial leadership for emerging and evolving public and private companies. Previously, he served as the Chief Financial Officer of Spinal Elements, Inc., a private equity backed medical device company.  Prior to Spinal Elements, Mr. Keyes was the Chief Financial Officer of Custopharm, Inc., a private equity backed developer of generic sterile injectable pharmaceuticals, where he helped lead the company through rapid commercial growth and successful acquisition by Hikma Pharmaceuticals.  Prior to Custopharm, Mr. Keyes held a variety of leadership roles in life science companies in finance, accounting, and mergers and acquisitions support, and he started his career in public accounting. Mr. Keyes has also served on the board of directors of CNS Pharmaceuticals, Inc., a public clinical stage biotech company, since June 2018. Mr. Keyes earned a B.A. degree in accounting from Western Washington University and is a certified public accountant.

Grace Johnston, Ph.D.

Chief Commercial Officer

Grace Johnston has served as our Chief Commercial Officer since December 2022. She previously served as Chief Commercial Officer at Fortis Life Sciences from September 2020 until December 2022, where she was accountable for organic revenue contribution, annual growth targets, commercial go-to-market strategy, sales and marketing, as well as overall customer experience. Prior to that, Dr. Johnston served in various roles of increasing responsibility at Sartorius AG from March 2016 until September 2020, most recently as Senior Vice President of Lab Product & Services – Marketing and Strategy, and previously as Vice President of Marketing for Essen Bioscience (acquired by Sartorius).

Prior to that, Dr. Johnston served in various roles of increasing responsibility at Merck KGaA-Millipore from 2009 to 2016, most recently as Head of Global Market Services & Strategy – Bioscience, and previously as Segment Market Manager and Product Manager Cell Analysis + Cell Culture Systems. Dr. Johnston received her Ph.D. in Molecular Neuroscience and B.A.s in Biology and Psychology from the University of Rochester, and participated in the Executive Leadership Program at Harvard Business School.

Todd Rearick

Chief Technology Officer

Todd Rearick has served as Quantum-Si’s Chief Technology Officer since January 2019. Prior to that Mr. Rearick served as Chief Technology Officer at Hyperfine Research from January 2018 to January 2019, and as Systems Engineer from June 2014 to January 2018. Prior to that Mr. Rearick was an Engineering Fellow at Life Technologies from October 2010 to June 2014, and Principal Engineer for Ion Torrent from May 2008 to October 2010.

Prior to that Mr. Rearick was a Software Manager at Raindance Technologies from June 2006 to May 2008, and held several positions at Sycamore Networks, a telecommunications equipment manufacturer, from April 1999 to June 2006. Mr. Rearick started his career with the Naval Undersea Warfare Center (NUWC) in New London, Connecticut from 1995 to 1998. Mr. Rearick earned his B.S. in Engineering Science from Penn State University.

Christian LaPointe, Ph.D.

General Counsel

Christian LaPointe, Ph.D. has served as Quantum-Si’s General Counsel since November 2020. Prior to joining Quantum-Si, Dr. LaPointe served as General Counsel at ArcherDX, Inc., a genomics company, from January 2015 to August 2019, and as Deputy General Counsel at ArcherDX from August 2019 to October 2020. Dr. LaPointe also served as General Counsel to Celsee, Inc., a single cell analysis solutions provider, from August 2019 to June 2020.

Previously, Dr. LaPointe was General Counsel at Thrive Bioscience, Inc., a cell culture instruments and software company, from August 2014 to July 2019, General Counsel of the Enzymatics enzyme solutions unit of QIAGEN N.V., from March 2013 to January 2015, General Counsel of Axios Biosciences, LLC, an oncology drug discovery company, from December 2012 to December 2014, and a litigation attorney at the law firm Sherin and Lodgen LLP from April 2012 to March 2013. Dr. LaPointe received his B.S. in biochemistry from the University of New Hampshire, his Ph.D. in biochemistry from Dartmouth College and his J.D. from Suffolk University Law School.